Rapport Therapeutics, Inc. (RAPP) stock
RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.76−1.06 (-4.27%)
Close on Nov 17, 2026Market cap $1.14BP/E –Yield –
Rapport Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Rapport Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$120.85M. For fiscal 2025 it was -$87.47M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$87.47M | – |
| FY2024 | Dec 31, 2024 | -$64.83M | – |
| FY2023 | Dec 31, 2023 | -$27.18M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$41.63M | – |
| Q2 FY2026 | Jun 30, 2026 | -$41.46M | – |
| Q1 FY2026 | Mar 31, 2026 | -$13.06M | – |
| Q4 FY2025 | Dec 31, 2025 | -$24.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.47M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$20.24M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.45M | – |
| Q3 FY2024 | Sep 30, 2024 | -$16.42M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.35M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.36M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.42M | – |
See a number that looks wrong?